3 ms·
It's definitely a different market than drugs with it's own set of challenges, but I'd say the lack of profitability has more to do with the disease state the v
by refurb 7y ago
It's definitely a different market than drugs with it's own set of challenges, but I'd say the lack of profitability has more to do with the disease state the vaccine is for versus the fact it's a vaccine.
And the global vaccine market is work $32B right now, so there is obviously a lot of profit being made.[1]
[1]https://www.prnewswire.com/news-releases/vaccine-market-size-expected-to-surpass-77-billion-at-103-cagr-by-2024--million-insights-681224391.html https://www.prnewswire.com/news-releases/vaccine-market-size...
- throwaway5752 7y agoLook, I get your point on disease state and I don't think companies are doing it for charity. But I don't think it's helpful to drop revenue figures absent margins. And it would be interest to see comparative global profits broken down along lines like Prevnar/Gardasil vs dtap/mmr. Nothing against the former, but when I consider deaths from preventable diseases like the latter it's kind of staggering the value we get for the money. $32B is the market cap of twitter.
- refurb 7y ago$32B is the market cap of twitter. You're mixing market cap with annual sales. Twitter's revenue was $2.61B last year.
- throwaway5752 7y agoI'm not conflating them, I'm using it to put it in perspective. It's common rhetorically and I assume the HN audience is smart enough to understand that.